| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 06/03/2009 | EP2064182A1 4-piperidylbenzamides as 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors |
| 06/03/2009 | EP2064181A1 4, 5-ring annulated indole derivatives for treating or preventing of hcv and related viral infections |
| 06/03/2009 | EP2064180A1 4,5-ring annulated indole derivatives for treating or preventing of hcv and related viral infections |
| 06/03/2009 | EP2064178A1 Prodrugs of inhibitors of cathepsin s |
| 06/03/2009 | EP2064174A1 Preparation of (r,r)-fenoterol and (r,r)- or (r,s)-fenoterol analogues and their use in treating congestive heart failure |
| 06/03/2009 | EP2064173A1 Crystalline form of cinacalcet |
| 06/03/2009 | EP2064170A2 Cyclohexenone and cyclohexanone derivatives |
| 06/03/2009 | EP2063963A2 Methods for treating cancer comprising the administration of a vitamin d compound and an additional therapeutic agent |
| 06/03/2009 | EP2063962A2 Irak modulators for treating an inflammatory condition, cell proliferative disorder, immune disorder |
| 06/03/2009 | EP2063912A2 Polyalkylene oxides having hindered ester-based biodegradable linkers |
| 06/03/2009 | EP2063903A1 Pulmonary surfactant formulations and methods for promoting mucus clearance |
| 06/03/2009 | EP2063901A2 Novel triclosan salts |
| 06/03/2009 | EP2063900A1 A cancer sensitizer comprising glucosamine, glucosamine derivatives or salts thereof |
| 06/03/2009 | EP2063899A2 Use of vitamin d compounds for the prevention of adhesions |
| 06/03/2009 | EP2063898A1 Use of equol for ameliorating or preventing neuropsychiatric and neurodegenerative diseases or disorders |
| 06/03/2009 | EP2063897A2 Kinase inhibitors useful for the treatment of proliferative diseases |
| 06/03/2009 | EP2063896A2 Kinase inhibitors useful for the treatment of proliferative diseases |
| 06/03/2009 | EP2063895A2 Combination drug |
| 06/03/2009 | EP2063894A2 Formulations containing pyridazine compounds for treating neuroinflammatory diseases |
| 06/03/2009 | EP2063893A2 3,4-dihydro-2 (1h) - quinolinone and 2 (1h)-quinolinone derivatives |
| 06/03/2009 | EP2063892A2 Methods and compositions for treating amyotrophic lateral sclerosis (als) |
| 06/03/2009 | EP2063891A2 Indoloquinoline compounds as calcium channel blockers |
| 06/03/2009 | EP2063890A1 Combination treatment for diabetes mellitus |
| 06/03/2009 | EP2063889A2 Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease |
| 06/03/2009 | EP2063888A1 Pharmaceutical composition comprising candesartan cilexetil |
| 06/03/2009 | EP2063887A2 New small molecule inhibitors of mdm2 and the uses thereof |
| 06/03/2009 | EP2063886A2 Use of n-containing spirocompounds for the enhancement of cognitive function |
| 06/03/2009 | EP2063885A2 Liquid and semi-solid pharmaceutical formulations for oral administration of a substituted amide |
| 06/03/2009 | EP2063884A1 Pro-oxidant anti-cancer compounds |
| 06/03/2009 | EP2063883A2 Binding interaction of proanthocyanidins with bacteria and bacterial components |
| 06/03/2009 | EP2063882A2 Tyrosine kinase inhibitors for prevention or treatment of infection |
| 06/03/2009 | EP2063881A2 A composition and method for the efficacious and safe administration of halopyruvate for the treatment of cancer |
| 06/03/2009 | EP2063880A2 Composition for the treatment of amyotrophic lateral sclerosis |
| 06/03/2009 | EP2063879A2 Compositions of chk1 inhibitors and cyclodextrin |
| 06/03/2009 | EP2063878A2 Bis(thiohydrazide amides) for use in preventing or delaying the recurrence of melanoma |
| 06/03/2009 | EP2063877A2 Drugs comprising at inhibitor of class i alpha mannosidase for the treatment of sarcoglycanopathies |
| 06/03/2009 | EP2063876A1 Extended release pharmaceutical formulation of metoprolol and process for its preparation |
| 06/03/2009 | EP2063871A1 Controlled release solid oral dosage formulations comprising nisoldipine |
| 06/03/2009 | EP2063870A2 Oral modified release formulations |
| 06/03/2009 | EP2063868A1 Pharmaceutical compositions containing rosuvastatin calcium |
| 06/03/2009 | EP2063867A2 Pharmaceutical compositions for treatment of parkinson's disease and related disorders |
| 06/03/2009 | EP2063865A1 Long term 24 hour intestinal administration of levodopa/carbidopa |
| 06/03/2009 | EP2063862A2 Pharmaceutical formulation for use in hiv therapy |
| 06/03/2009 | EP2063861A2 Dosage unit for sublingual, buccal or oral administration of water-insoluble pharmaceutically active substances |
| 06/03/2009 | EP2063710A2 Difluorinated piperidines for treatment of alzheimer's disease and related conditions |
| 06/03/2009 | EP2063709A2 Hindered ester-based biodegradable linkers for oligonucleotide delivery |
| 06/03/2009 | EP2063708A2 Liquid pharmaceutical formulations for oral administration of a cgrp antagonist |
| 06/03/2009 | EP1940247B1 Method for stimulating intestinal barrier integrity after non-natural birth |
| 06/03/2009 | EP1910381B1 Substituted 1-oxa-3,8-diazaspiro[4.5]-decan-2-on- compounds and the use thereof for producing drugs |
| 06/03/2009 | EP1910310B1 Novelimidazolecarboxamide derivatives as fructose-1,6-bisphosphatase inhibitors, and pharmaceutical compositions comprising same |
| 06/03/2009 | EP1906912A4 Method for prolonging the life of animals |
| 06/03/2009 | EP1863469A4 A topical analgesic composition |
| 06/03/2009 | EP1814860B1 Substituted 5-carboxyamide pyrazoles and [1,2,4]triazoles as antiviral agents |
| 06/03/2009 | EP1807062A4 Use of androgens to reduce the likelihood of acquiring or to treat skin aging |
| 06/03/2009 | EP1786790B1 Oxazole derivatives as histamine h3 receptor agents, preparation and therapeutic uses |
| 06/03/2009 | EP1765788B1 3-aminoindazole derivatives and their use for the treatment of sgk-associated diseases |
| 06/03/2009 | EP1758904B1 Flavopereirine derivatives for cancer therapy |
| 06/03/2009 | EP1742710B1 Stabilized ascorbic acid compositions and methods therefor |
| 06/03/2009 | EP1742628A4 Alternative forms of the phosphodiesterase-4 inhibitor n-cyclopropyl-1-{3-¬(1-oxidopryidin-3-yl)ethynyl phenyl}-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxyamide |
| 06/03/2009 | EP1732535B1 Injectable composition for the treatment of cancers |
| 06/03/2009 | EP1696912A4 Pyrazolopyridines and analogs thereof |
| 06/03/2009 | EP1682546B1 Peptidomimetic compounds, stereoselective process for their preparation, their use as biologically active synthetic intermediates |
| 06/03/2009 | EP1667679B1 Aminobenzimidazoles as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders |
| 06/03/2009 | EP1660077B1 Indol-6 sulfonamide derivatives, their preparation and their use 5-ht-6 as modulators |
| 06/03/2009 | EP1648446B1 Indol-4 sulfonamide derivatives, their preparation and their use 5-ht-6 as modulators |
| 06/03/2009 | EP1648445B1 Indol-5-yl sulfonamide derivatives, their preparation and their use 5-ht-6 as modulators |
| 06/03/2009 | EP1648444B1 Indol-7 sulfonamide derivatives, their preparation and their use 5-ht-6 as modulators |
| 06/03/2009 | EP1648431B1 Novel use of a polyamine-poor composition for the production of a medical human food |
| 06/03/2009 | EP1633339A4 Formulations of non-steroidal anti-inflammatory agents to treat pathologic ocular angiogenesis |
| 06/03/2009 | EP1613319B1 Substituted phenyl acetamides and their use as protease inhibitors |
| 06/03/2009 | EP1608656B1 Imidazotriazine compounds for the treatment of cancer diseases |
| 06/03/2009 | EP1608350B1 Methods of preventing, treating and diagnosing disorders of protein aggregation |
| 06/03/2009 | EP1606288B1 Benzenesulphonamide derivatives, method for production and use thereof for treatment of pain |
| 06/03/2009 | EP1575533B1 Topical compositions having a natural ingredient and method of use |
| 06/03/2009 | EP1567145B1 Analgesic uses of (s)-norketamine |
| 06/03/2009 | EP1480618B1 Sustained release drug formulations containing a carrier peptide |
| 06/03/2009 | EP1435906B1 Method for producing biologically active products |
| 06/03/2009 | EP1399440B1 5-(2-aminopyrimidin-4-yl)benzisoxazoles as protein kinase inhibitors |
| 06/03/2009 | EP1366759B1 Tablets quickly disintegrating in oral cavity |
| 06/03/2009 | EP1313737B1 Novel guanidino derivatives as inhibitors of cell adhesion |
| 06/03/2009 | EP1307454B1 Derivatives of variolin b |
| 06/03/2009 | EP1263720B1 Azetidine derivatives, preparation thereof and pharmaceutical compositions containing same |
| 06/03/2009 | EP1253853B1 Method for classifying physiologic brain imbalances using quantitative eeg |
| 06/03/2009 | EP1218544B1 TAR RNA binding peptides |
| 06/03/2009 | EP1165553B1 C10 ester substituted taxanes as antitumor agents |
| 06/03/2009 | EP1140079B1 Assays for ligands for nuclear receptors |
| 06/03/2009 | EP1131426B1 Mage-10 or mage-8 derived hla-a2.1-binding oligopeptides |
| 06/03/2009 | EP1071668B1 5-aminoindeno[1,2-c]pyrazol-4-ones as anti-cancer and anti-proliferative agents |
| 06/03/2009 | EP1035836B1 Composition comprising an enzym, a stabilizer for the enzym and a process for ameliorating the stability of the enzyme, to prevent its degradation, to protect it and/or to immobilise it |
| 06/03/2009 | EP0928184B1 Anti-caries oral compositions |
| 06/03/2009 | EP0833649B2 Methods of preventing or treating allergies |
| 06/03/2009 | CN101448508A Methods of treating degenerative disorders with RAC 1B inhibitor |
| 06/03/2009 | CN101448507A Solid preparation comprising adenosine 5'-triphosphate or physiologically acceptable salt thereof |
| 06/03/2009 | CN101448506A Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase |
| 06/03/2009 | CN101448505A P13 kinase antagonists |
| 06/03/2009 | CN101448504A Crystalline forms of gemcitabine amide prodrug, compositions and use thereof |
| 06/03/2009 | CN101448503A Piperidine and piperazine derivatives |
| 06/03/2009 | CN101448502A Terguride/proterguride for the treatment of chronic pain |
| 06/03/2009 | CN101448501A Combination therapy for the treatment of cancer |
| 06/03/2009 | CN101448500A Combination therapies of thiazolidinedione analogues and glucocorticoid agonists |